IMUX Immunic Inc.

14
+0.05  (+0%)
Previous Close 13.95
Open 13.95
Price To Book 15.38
Market Cap 139,809,586
Shares 9,986,399
Volume 9,936
Short Ratio
Av. Daily Volume 185,189

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim dosing analysis expected mid-2019 and top-line data expected 2Q 2020.
IMU-838
Ulcerative colitis
Phase 2 data due 3Q 2020.
IMU-838
Relapsing-remitting multiple sclerosis
Phase 2 trial to commence April 12, 2019.
IMU-838
Crohn’s disease